Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization by Lenzen, M.J. et al.
Clinical research
Management and outcome of patients with
established coronary artery disease: the
Euro Heart Survey on coronary revascularization
M.J. Lenzen1, E. Boersma1, M.E. Bertrand2, W. Maier3, C. Moris4, F. Piscione5,
U. Sechtem6, E. Stahle7, P. Widimsky8, P. de Jaegere1,
W.J.M. Scholte op Reimer1, N. Mercado1, and W. Wijns9*
1Department of Cardiology, Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
2Division of Cardiology, Lille University Heart Institute, Lille, France
3Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
4Cardiology Service, Hospital Central de Asturias, Asturias, Spain
5Division of Cardiology, Federico II University, Naples, Italy
6Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
7Thoracic and Cardiovascular Surgery, University Hospital, Uppsala, Sweden
8University Hospital Vinohrady, Prague, Czech Republic
9Cardiovascular Centre, OLV Hospital, 164 Moorselbaan, B 9300 Aalst, Belgium
Received 6 December 2004; revised 10 February 2005; accepted 23 February 2005; online publish-ahead-of-print 31 March 2005
See page 1147 for the editorial comment on this article (doi:10.1093/eurheartj/ehi247)
Aims The purpose of the Euro Heart Survey Programme of the European Society of
Cardiology is to evaluate to which extent clinical practice endorses existing guidelines
as well as to identify differences in population proﬁles, patient management, and
outcome across Europe. The current survey focuses on the invasive diagnosis and
treatment of patients with established coronary artery disease (CAD).
Methods and results Between November 2001 and March 2002, 7769 consecutive
patients undergoing invasive evaluation at 130 hospitals (31 countries) were screened
for the presence of one or more coronary stenosis .50% in diameter. Patient demo-
graphics and comorbidity, clinical presentation, invasive parameters, treatment
options, and procedural techniques were prospectively entered in an electronic data-
base (550 variablesþ 29 per diseased coronary segment). Major adverse cardiac
events (MACE) were evaluated at 30 days and 1 year. Out of 5619 patients with angio-
graphically proven coronary stenosis (72% of screened population), 53% presented with
stable angina while ST elevation myocardial infarction (STEMI) was the indication for
coronary angiography in 16% and non-ST segment elevation myocardial infarction or
unstable angina in 30%. Only medical therapy was continued in 21%, whereas mecha-
nical revascularization was performed in the remainder [percutaneous coronary inter-
vention (PCI) in 58% and coronary artery bypass grafting (CABG) in 21%]. Patients
referred for PCI were younger, were more active, had a lower risk proﬁle, and
had less comorbid conditions. CABG was performed mostly in patients with left
main lesions (21%), two- (25%), or three-vessel disease (67%) with 4.1 diseased seg-
ments, on average. Single-vessel PCI was performed in 82% of patients with either
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single- (45%), two- (33%), or three-vessel disease (21%). Stents were used in 75% of
attempted lesions, with a large variation between sites. Direct PCI for STEMI was per-
formed in 410 cases, representing 7% of the entire workload in the participating
catheterization laboratories. Time delay was within 90 min in 76% of direct PCI
cases. In keeping with the recommendations of practice guidelines, the survey ident-
iﬁed under-use of adjunctive medication (GP IIb/IIIa receptor blockers, statins, and
angiotensin-converting enzyme-inhibitors). Mortality rates at 30 days and 1 year
were low in all subgroups. MACE primarily consisted of repeat PCI (12%).
Conclusion The current Euro Heart Survey on coronary revascularization was per-
formed in the era of bare metal stenting and provides a global European picture of
the invasive approach to patients with CAD. These data will serve as a benchmark
for the future evaluation of the impact of drug-eluting stents on the practice of inter-
ventional cardiology and bypass surgery.
Introduction
The management of patients with coronary artery
disease (CAD) is complex. Better understanding of the
pathophysiology of the disease and the introduction of
novel diagnostic techniques in conjunction with novel
or more powerful pharmacologic and revascularization
therapies mandate continuous reassessment and evalu-
ation of medical practice.1–6
Practice guidelines for diagnostic procedures and
patient management are established to help cardiologists
in every-day clinical decision making. The scientiﬁc foun-
dation for these guidelines is provided by randomized
clinical trials, although non-randomized trials, retrospec-
tive studies, or consensus opinion of experts are also
used.7–9
The European Society of Cardiology (ESC) is dedicated
to improve health by reducing the impact of cardiovascu-
lar disease by various means. The Euro Heart Survey pro-
gramme is meant to evaluate to which extent clinical
practice endorses existing guidelines as well as to iden-
tify differences in population proﬁles, patient manage-
ment, and outcome across Europe.10
The current survey focuses on patients with at least
one .50% diameter stenosis, visualized during coronary
angiography, who are potential candidates for coronary
revascularization.
Methods
The Euro Heart Survey on coronary revascularization was
conducted in 130 voluntary participating hospitals from 31 ESC
member countries, with the objective to evaluate clinical prac-
tice, adherence to guidelines, differences in the management,
and outcome of patients and to assess to what extent the
patients of daily practice are represented in randomized clinical
trials. Participating hospitals represent both academic (40%) and
non-academic (60%) institutions with (83%) and without (17%)
cardiac surgery and/or interventional cardiology facilities.
These centres were asked to enrol blocks of 40 consecutive
patients. The present survey was designed to screen all conse-
cutive patients undergoing invasive diagnostic or therapeutic
catheterization, of which all patients with .50% diameter
stenoses in at least one major epicardial vessel were asked to
participate. In each hospital, data (550 patient variables and
29 variables per treated coronary segment) were collected by
data collecting ofﬁcers on computers, using the MacroTM soft-
ware (InferMed, UK) and sent through the internet to a central
database located at the European Heart House. The software
used implemented internal edit checks for missing or contra-
dictory entries or for values out of the normal range. The data
management staff of the European Heart House performed
additional edit checks. Canadian Class Society (CCS) functional
class and risk stratiﬁcation were evaluated prospectively in
patients with stable angina.11,12 The EuroSCORE and TIMI risk
score were calculated from the available variables.13,14
The survey on coronary revascularization was conducted
between November 2001 and March 2002. One year follow-up
was made by personal or telephone contact and available in
4770 patients (83%). Fourteen hospitals (11%) were not able to
provide follow-up information. Median (quartiles) follow-up
period was 12 months (11–13 months). Statistical analyses
were carried out with SPSS statistical software (version 12.0
for Windows), using mostly descriptive statistics between
subsets of patients deﬁned by treatment preference. Results
are presented as mean and median with corresponding values
(SD and inter-quartile ranges, respectively) and as per cent.
Given the large sample size, P-value of 0.001 was considered
statistically signiﬁcant.
Results
A total of 7769 patients undergoing coronary angiography
were screened, of whom 5767 fulﬁled the inclusion
criteria. Patients with either insufﬁcient or invalid data
(n ¼ 148) were excluded from further analysis. Therefore,
the total population of the present report amounts to
5619. The baseline characteristics are summarized in
Table 1. Stable angina was the most frequent indication
to perform angiography (53%), followed by non-ST
segment elevation myocardial infarction (NSTEMI) or
unstable angina (UA) (30%) and ST elevation myocardial
infarction (STEMI) (16%). In 2002 of the screened patients
(24%), no CAD or stenosis ,50% was found. Absence of
signiﬁcant CAD differed between patients with acute
coronary syndrome (ACS) (16%) and stable ischaemic
heart disease (35%) but was most prevalent when CAD
was not the primary reason for performing angiography
(48%).
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Mechanical revascularization [percutaneous coronary
intervention (PCI): 58%, CABG: 21%] was often performed
or planned, whereas a substantial number of patients
were continued on medical treatment (21%). PCI was pre-
dominantly performed in patients admitted with ACS
with or without ST-segment elevation or UA (53%),
whereas CABG and medical treatment were applied
mostly in patients with stable angina (64 and 61%,
respectively). Patients who underwent PCI were, in
general, younger, more active, and with fewer comorbid
conditions. Patients who received medical therapy had a
higher prevalence of previous bypass surgery and myocar-
dial infarction (Table 1 ).
Of all diseased segments at coronary angiography
(15 856), 51% was considered suitable for PCI and 69%
for CABG, whereas 24% of the lesions (1597 patients)
were judged as only suitable for CABG, not for PCI.
Most of the lesions unsuitable for PCI were totally
occluded (70%) or located in the left main (20%). PCI
was predominantly performed in patients with single-
vessel disease and preserved ventricular function
(Table 2). Nonetheless, two- and three-vessel disease
was present in 33 and 21%, respectively, suggesting
incomplete revascularization by anatomy. Single-PCI
was performed in 82% of all cases and the attempted
lesions were of type A in 15%, B in 50%, and C in 12%.
Bypass surgery was mainly performed in patients with
three-vessel disease (67%), left main stem stenosis,
(21%) or extensive disease as reﬂected by the mean
number of diseased segments (4.1). The left anterior des-
cending coronary artery (LAD) was diseased in 90% of all
patients undergoing CABG and extracorporeal circulation
was used in 81% of all operations.
Patients who received only medical therapy had
a higher prevalence of advanced disease when
compared with PCI patients (61 vs. 54% multi-vessel
disease, 2.9 vs. 2.3 diseased segments). Angiographic
proﬁle was worst in those who underwent CABG
(92% multi-vessel disease, 4.1 diseased segments). It is
worth noting that patients treated medically had the
highest prevalence of poor ventricular function.
Although the reason for choosing medical treatment
was largely related to the clinical presentation and
the severity and extent of CAD, we also observed large
differences in treatment options between participating
hospitals (Figure 1 ). Apart from contraindications
for mechanical revascularization (i.e. vessels not
suitable: 34%; high-risk procedure: 17%), 13% of the
medically treated patients had refused mechanical
revascularization.
Table 1 Clinical characteristics of total cohort and patients in different treatment groups
Total
(n ¼ 5619)
PCI
(n ¼ 3254)
CABG
(n ¼ 1188)
Medical
(n ¼ 1177)
P-value
Age (mean+ SD) 63.2+ 10.8 62.4+ 11.2 64.5+ 10.0 64.3+ 10.6 
Male gender, n (%) 4268 (76) 2448 (75) 933 (79) 887 (75)
Smoking, n (%)
Current 1411 (25) 912 (28) 262 (22) 237 (20)
Past 1924 (34) 1045 (32) 434 (37) 445 (38)g 
Never 2084 (37) 1170 (36) 452 (38) 462 (39)
Diabetes mellitus, n (%)
Type 1 208 (4) 121 (4) 38 (3) 49 (4)
Type 2 1130 (20) 603 (19) 261 (22) 266 (23)
Hypercholesterolaemia, n (%) 3591 (65) 2130 (67) 737 (64) 724 (64)
Hypertension, n (%) 3315 (60) 1851 (57) 714 (61) 750 (64) 
Sedentary lifestyle, n (%) 1601(40) 869 (37) 357 (43) 375 (45) 
Congestive heart failure, n (%) 1026 (18) 457 (14) 279 (24) 290 (25) 
Chronic lung disease, n (%) 492 (9) 273 (8) 106 (9) 113 (10)
Chronic renal failure, n (%) 226 (4) 137 (4) 33 (3) 56 (5)
Peripheral vascular disease, n (%) 657 (12) 330 (10) 169 (14) 158 (14) 
Cerebrovascular disease, n (%) 427 (8) 205 (6) 116 (10) 106 (9) 
Comorbidity per patienta (mean+ SD) 0.5+ 0.8 0.4+ 0.7 0.6+ 0.8 0.6+ 0.8 
Risk factors per patientb (mean+ SD) 2.1+ 1.0 2.1+ 0.9 2.1+ 1.0 2.1+ 1.0
Prior CABG, n (%) 601 (11) 307 (10) 41 (4) 253 (22) 
Prior PCI, n (%) 1140 (20) 738 (23) 130 (11) 272 (23) 
Prior MI, n (%) 2258 (39) 1168 (36) 448 (38) 542 (47) 
Diagnosis at admission, n (%)
Stable angina 2936 (53) 1503 (47) 743 (64) 690 (61)
Non-ST elevation ACS/UA 1672 (30) 1014 (31) 331 (28) 327 (29)g 
ST elevation MI 906 (16) 710 (22) 88 (8) 108 (10)
Duration of hospitalization in days
(median–IQR)c
5 (3—11) 4 (3—8) 12 (7—22) 4 (2—10) 
Proportions are given per column. Asterisks denote P  0.001; MI, myocardial infarction.
aComborbidity included congestive heart failure, chronic lung disease, renal failure, peripheral vascular disease, and cerebrovascular disease.
bRisk factors included, smoking (ever), diabetes, hypercholestaerolaemia, and hypertension.
cData known in 5291 cases (3142 PCI, 1102 CABG, 1047 Medical).
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In conjunction with the differences in baseline charac-
teristics, the total and average number of attempted seg-
ments differed between PCI- and CABG-treated patients
(Table 2 ). The large majority of patients undergoing
PCI (84%) was treated within 30 days, whereas only 50%
of CABG patients were treated within this period. The
majority of patients undergoing PCI (59%) underwent
the procedure within 24 h after diagnostic angiography.
There was a strikingly high use of stents (applied in 72%
of all attempted segments and 75% of PCI patients)
while at least one arterial graft was implanted in 89%
of the surgical procedures. The variation in the use of
stents in participating hospitals was huge as illustrated
in Figure 2. The assessment of procedure-related
myocardial injury from serial sampling of necrosis
markers was only performed in 61% of PCI and 31% of
CABG cases. In accordance with guidelines, consensus
statements and data from clinical trials, PCI patients at
increased risk (diabetes, ACS) should receive peri-
procedural GP IIb/IIIa receptor blockers. GP IIb/IIIa
receptor blockers were used only in 27% of all PCI pro-
cedures. Almost half (46%) of all STEMI patients under-
going primary PCI (n ¼ 393) were treated with GP
IIb/IIIa receptor blockers. In NSTEMI/UA patients under-
going PCI within 30 days after angiography, 32% received
GP IIb/IIIa receptor blockers, mostly because of high-risk
features (60%). Among PCI patients with stable angina,
14% received GP IIb/IIIa receptor blockers and 23% were
on thienopyridine treatment prior to the intervention.
No difference in GP IIb/IIIa receptor blocker use was
observed between patients with or without diabetes
mellitus. Furthermore, we observed large differences in
the use of GP IIb/IIIa receptor blockers between the
participating hospitals (Figure 3 ).
In most patients with stable angina, CCS was known
(96%). Almost two-thirds of these patients were in CCS
class 1 or 2 (Table 3 ). Patients in CCS 3 or 4 were more
likely to be classiﬁed as high-risk patients when com-
pared with patients in CCS 1 or 2 (23 vs. 13%).
Comparison of this risk stratiﬁcation with the EuroSCORE
revealed a mean score of 3.3 in low-risk patients, 3.7 in
intermediate-risk patients, and 4.4 in high-risk patients.
When calculating the EuroSCORE per treatment-group in
patients with stable angina and NSTEMI/UA, we observed
a lower risk in PCI patients when compared with CABG
and medically treated patients (Table 4 ). In NSTEMI/UA
patients, the TIMI score was similar among the three
treatment options (mean score 3.1+ 1.1). Despite the
proven CAD, a normal ECG was present in 23% of all
NSTEMI/UA cases.
High-risk features or recurrent/persistent angina in
NSTEMI/UA patients and recurrent ischaemia or compli-
cations in STEMI patients were the most frequent
indications for angiography (62 and 42%, respectively).
Cardiogenic shock was registered in 8% of STEMI patients.
The rate of reperfusion therapy including ﬁbrinolytic
treatment and primary PCI in this selected group of
STEMI patients who reached the catheterization labora-
tory was 64%, of which 68% underwent primary PCI. The
median time from admission to the intervention was
45 min (inter-quartile range: 15–90 min) and the pro-
cedure started within 90 min after admission in 76%,
Table 2 Angiographic results based on chosen treatment option
Total
(n ¼ 5619)
PCI
(n ¼ 3254)
CABG
(n ¼ 1188)
Medical
(n ¼ 1177)
P-value
Severity of CAD, n (%)a
Single-vessel disease 2010 (36) 1469 (45) 87 (7) 454 (39)
Two-vessel disease 1701 (30) 1086 (33) 298 (25) 317 (27)g 
Three-vessel disease 1882 (34) 687 (21) 797 (67) 398 (34)
Left main lesions 476 (9) 126 (4) 251 (21) 99 (8) 
Diseased segments
Mean number of diseased segments, SD 2.8+ 1.9 2.3+ 1.7 4.1+ 1.9 2.9+ 2.1 
% valued as suitable for PCI 51 69 37 32 
% valued as suitable for CABG 69 63 91 52 
Left ventricular function known, n (%) 4854 (86) 2732 (84) 1096 (92) 1026 (87)
Ejection fraction .50% 2904 (60) 1726 (63) 633 (58) 545 (53)
Ejection fraction 40–50% 1281 (26) 710 (26) 295 (27) 276 (27)g 
Ejection fraction ,40% 669 (14) 296 (11) 168 (15) 205 (20)
Intervention performed within
30 days after angiography, n (%)
3339 2744 (84) 595 (50) —
Total number of attempted
segments/diseased segmentsb
5426 3564/6477 (55) 1862/2483 (75) —/3404 (0)
Attempted segments per patient, meanb — 1.30 3.13 —
Successfully dilated/bypassed segments (%)b — 95 96 —
Procedural techniques
Stenting (%)b — 2050 (75) — —
One or more arterial graft (%)b — — 531 (89) —
Proportions are given per column. Asterisks denote P  0.001.
aDue to missing data (.1%) not counting up to total number of patients.
bOn the basis of number (%) of patients who underwent the intervention within 30 days after angiography.
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Figure 1 Visualizes the per cent of invasive (PCI and CABG) and medically treated patients in hospitals participating in the Euro Heart Survey on
coronary revascularization. Hospitals are ordered on the basis of patients referred for PCI. It should be noted that the ordering of hospital differs
between the three ﬁgures.
Figure 2 The variation in use of stents per hospital in patients who underwent PCI within 30 days after diagnostic angiography. It should be noted that
the ordering of hospital differs between the three ﬁgures.
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indicating that the majority of patients was treated
within the advocated timeframe of 90 min. It should be
noted, however, that no information on in-hospital time
delay was available in 28% of patients. Delayed angiogra-
phy was performed on a systematic basis in 44% of the
513 STEMI patients who did not undergo primary PCI.
Of the 5619 participating patients, 1.9% (104 patients)
died within 30 days. The overall 1 year mortality was
4.7% (263 patients). The mortality differed between diag-
nosis and treatment groups (Table 4 ). One-year mortality
was lowest in patients with stable angina who underwent
PCI (1.9%) and highest in STEMI patients not undergoing
mechanical revascularization (8.4%). However, a signiﬁ-
cantly reduced 1 year mortality between the three treat-
ment groups was observed only in patients with stable
angina, reﬂecting the large proportion of low-risk
patients undergoing PCI.
After 1 year, 13% of the PCI patients required repeat
revascularization (10% at least one repeat PCI, 3% were
operated), whereas only 1% of patients initially treated
with CABG needed repeat revascularization. A small pro-
portion of patients who were initially treated medically
underwent mechanical revascularization eventually
(4%). Rehospitalization for cardiac reasons was more fre-
quent in PCI and medical patients (28 and 25%, respec-
tively), when compared with those undergoing CABG
(15%).
At discharge, most patients (.90%) were prescribed at
least one anti-thrombotic drug (either aspirin, thieno-
pyridine, or anticoagulants), irrespective of treatment
Figure 3 The variation in the use of GP IIa/IIIb receptor blockers stents per hospital in patients who underwent PCI within 30 days after diagnostic angio-
graphy. It should be noted that the ordering of hospital differs between the three ﬁgures.
Table 3 Risk assessment and outcome in patients with stable angina
Estimated risk of Canadian class Total
2936 (53)
1 year
mortality
1 year mortality/
non-fatal MI
1 year mortality/non-fatal MI/
rehospitalization for cardiac reason
CCS 1 or 2, n (%) 1795 (63)
Unknown 203 (11) 5 (3) 9 (4) 51 (25)
Low (,1% annual mortality) 536 (30) 14 (3) 22 (4) 108 (20)
Intermediate (1–3% annual mortality) 818 (46) 16 (2) 27 (3) 156 (19)
High (.3% annual mortality) 238 (13) 10 (4) 13 (6) 59 (25)
CCS 3 or 4, n (%) 1037 (37)
Unknown 144 (14) 7 (5) 10 (7) 35 (24)
Low (,1% annual mortality) 158 (15) 8 (5) 10 (6) 42 (27)
Intermediate (1–3% annual mortality) 496 (48) 18 (4) 26 (5) 120 (24)
High (.3% annual mortality) 239 (23) 18 (8) 20 (8) 69 (29)
Proportions are given per row.
Values in parentheses are percentages.
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allocation (Table 5 ). When coronary stenting was
performed, 94% were discharged on clopidogrel or
ticlopidine. Other prophylactic drug classes such as
beta-blockers, angiotensin-converting enzyme-inhibitors
(ACE-inhibitors), and statins were used less frequently.
Except for beta-blockers, comparison between the
three treatment groups revealed signiﬁcant differences
in prescription proﬁle. At 1 year follow-up, pharmaco-
logical treatment remained unchanged and below the
target. Only the use of statins increased from discharge
(54%) to 1 year in patients undergoing CABG (69%), but
remained below the target.
Discussion
Acute presentations of CAD represented the primary indi-
cation for diagnostic angiography in 46% of all cases,
whereas in patients with stable angina, the selection of
patients to undergo diagnostic angiography was based
on symptomatic status and/or risk evaluation. In line
with previous reports, we observed a global normalcy
rate of 24%.10,15 This proportion was higher when the
primary diagnosis leading to the angiography was stable
angina rather than acute CAD. An indication for mecha-
nical revascularization followed the diagnostic angiogram
in 57% of all cases screened and in 79% of those with at
least one signiﬁcant stenosis, indicating appropriate use
of this invasive and expensive diagnostic procedure.
This survey of current practice in Europe shows a clear
preference for PCI over CABG (ratio 3:1), possibly
suggesting under-use of the more invasive bypass
operation.16
In accordance with the guidelines, patients selected
for CABG were sicker and had more extensive CAD;
however, a sizable proportion of patients with multi-
vessel or left main disease, impaired left ventricular
function or diabetes did not undergo bypass surgery.
Patient and/or physician preference as well as the
shorter time delay between angiography and PCI (com-
pared with time delay between angiography and CABG)
may have contributed to this choice. In patients with
multi-vessel disease, recent meta-analyses show no diffe-
rence in the rate of major irreversible adverse events
between PCI and CABG.17,18 However, after 1 year
follow-up, repeat PCI was performed in 10 and 3%
eventually required CABG, indicative of the lower
durability of the result after PCI. Coronary stenting
using bare metal devices was applied in 72% of all
segments and PCI was limited to a single-vessel in 82%
of cases. Use of stents varied widely from 0% in two
hospitals to 100% in 17 hospitals, a wide range that prob-
ably relates to differences in local reimbursement poli-
cies. It should be remembered that all data from the
current survey have been acquired prior to the clinical
availability of drug-eluting stents. Increased availability
of these more durable devices will likely increase the
conﬁdence of interventional cardiologists in treating
more complex patient and/or lesion subsets by means
of PCI.19
Table 4 Risk assessment and outcome in three different diagnosis groups, based on treatment option
Total PCI CABG Medical P-value
Stable angina, n 2936 1503 743 690
Duration of hospitalization in days (median–IQR) 3 (2–9) 3 (2–5) 10 (5–18) 3 (2–6) 
EuroSCORE (mean+ SD) 3.8+ 2.7 3.3+ 2.4 4.4+ 3.0 4.2+ 2.6 
30 day mortality, n (%) 25 (1) 5 (0) 17 (2) 3 (0) 
Total mortality at 1 year, n (%) 101 (3) 28 (2) 41 (6) 32 (5) 
Non-fatal MIa, n (%) 41 (2) 24 (2) 8 (1) 9 (2)
Rehospitalization for cardiac reasona, n (%) 559 (24) 354 (29) 80 (14) 125 (23) 
(Repeat) Revascularizationa, n (%) 183 (7) 150 (12) 6 (1) 27 (5) 
NSTEMI/UA, n 1672 1014 331 327
Duration of hospitalization in days (median, IQR) 7 (3–12) 5 (3–10) 16 (9–25) 7 (3–12) 
EuroSCORE (mean+ SD) 5.8+ 2.8 5.4+ 2.6 6.1+ 3.2 6.5+ 2.8 
30 day mortality, n (%) 35 (2) 19 (2) 8 (2) 8 (2)
Total mortality at 1 year, n (%) 82 (5) 41 (4) 17 (5) 24 (7)
Non-fatal MIb, n(%) 43 (3) 30 (4) 11 (4) 2 (1)
Rehospitalization for cardiac reasonb, n (%) 376 (29) 249 (31) 48 (19) 78 (31) 
(Repeat) Revascularizationb, n (%) 133 (10) 119 (14) 5 (2) 9 (3) 
STEMI, n 906 710 88 108
Duration of hospitalization in days (median–IQR) 7 (4–12) 7 (4–11) 13 (9–27) 9 (4–18) 
30 day mortality, n (%) 42 (5) 30 (4) 7 (8) 5 (5)
Total mortality at 1 year, n (%) 67 (7) 51 (7) 7 (8) 9 (8)
Non-fatal MIc, n (%) 18 (3) 13 (3) 2 (3) 3 (4)
Rehospitalization for cardiac reasonc, n (%) 148 (23) 122 (24) 7 (11) 19 (24)
(Repeat) Revascularizationc, n (%) 63 (9) 58 (11) 0 5 (6)
Asterisks denote P  0.001.
aData known in 2472 patients, 84% of patients with stable angina (1279 PCI, 608 CABG, 585 Medical).
bData known in 1403 patients, 84% of patients with NSTEMI/UA (862 PCI, 267 CABG, 274 Medical).
cData known in 704 patients, 78% of patients with STEMI (550 PCI, 66 CABG, 88 Medical).
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Another proportion of patients who were at high risk
did not undergo revascularization. This probably results
from the limitations of currently available mechanical
revascularization procedures in treating diffuse disease
or from the poor general condition of some patients
unable to undergo an invasive treatment or from the esti-
mated unacceptably high procedural risks.
Despite their proven beneﬁcial effects in high-risk
patients (e.g. diabetes) and/or procedures,20,21 overall
a sizable proportion of patients fulﬁling these criteria
did not receive GP IIb/IIIa receptor blockers. In addition,
major variations across European hospitals in the use of
GP IIb/IIIa receptor blockers were observed. Most surpris-
ing was the low use of these drugs in diabetic patients
undergoing PCI for stable angina (15%). Also of concern
was the failure to measure post-procedural necrosis
markers in 39% of all PCI procedures. Increased levels
of cardiac enzymes are indeed an independent predictor
of cardiac mortality and subsequent myocardial infarc-
tion.22,23 Similarly, in patients undergoing CABG, necrosis
markers were measured in only one-third, most likely
reﬂecting the disputable value of these markers following
surgery.24
As to the treatment of STEMI, this survey concurs with
previous studies in showing that reperfusion treatment
remains underused,25 even in this selected subgroup of
patients referred for angiography. By design, we cannot
analyse the factors that contribute to this sobering obser-
vation. In accordance with the guidelines, primary PCI is
the preferred treatment for STEMI, provided this pro-
cedure can be performed by an experienced team within
90 min after ﬁrst medical contact.9 It was encouraging to
observe that the majority of patients undergoing primary
PCI was treated within the advocated timeframe of
90 min. However, due to missing admission or procedure
times, the in-hospital delay was unknown in a sizeable
proportion of patients. The current prospective survey
clearly shows that in clinical practice, reporting of all
relevant time intervals was not optimal. This failure
stresses the importance of a thorough registration as
well as the need for implementing in each institution
appropriate procedures and pathways that will permit
to select the optimal treatment for an individual
patient.26,27
The overall mortality ﬁgures were low (1.9% at 30 days
and 4.7% at 1 year) in all patient groups and treatment
modalities, even after risk-adjustment using for instance
the EuroSCORE. As expected, 1 year mortality rate was
larger in STEMI (7%) and in NSTEMI/UA (5%) compared
with stable angina patients (3%).
Patients with established CAD enrolled in this survey
should beneﬁt from secondary prevention measures.28
Changing the patient risk behaviour (unhealthy diet,
smoking, and sedentary lifestyle) and prescribing drugs
with proven prophylactic effects are essential aspects
of current treatment, even after mechanical revas-
cularization.29–33 Furthermore, effective secondary
prevention in clinical practice, using evidence-based
treatment, has been proven effective in reducing
the composite of death, myocardial infarction, and
stroke.34,35 Although the majority of patients used anti-
thrombotics and beta-blockers, as recommended, ACE-
inhibitors were underused in all subgroups and statins
were particularly underused after CABG. Overall, pre-
scription of these prophylactic drugs was increased
when compared with EuroAspire II,36 indicating that
time is required before guidelines are progressively
endorsed. In any case, the moment that patients are
admitted in the hospital to undergo an invasive pro-
cedure should be taken as an opportunity to further opti-
mize their pharmacological treatment.
The limitations of this study are those inherent to
observational surveys involving voluntarily participating
hospitals. Although we have attempted to include a wide
spectrum of hospitals in different countries, almost
certainly the results are biased towards better than
average practices. The sample size only represents a
small fraction of all patients admitted in catheterization
laboratories throughout Europe during the study period.
Nevertheless, because patient inclusion was consecutive
at the participating sites, we trust that the survey depicts
the ongoing clinical practice. Data on the 1 year follow-
up were not obtainable in 14 hospitals (from 10 countries)
because of management problems unrelated to individual
patient characteristics. Presumably, this did not intro-
duce signiﬁcant selection bias. Data quality was checked
through queries for missing or contradictory entries.
However, no site visits or source data veriﬁcation was
performed. However, since many participating sites are
part of other Euro Heart Surveys, their performance is
regularly evaluated.
To summarize, the current Euro Heart Survey on coron-
ary revascularization provides a global European picture
of the invasive approach to patients with CAD, as they
present with either stable angina, STEMI or NSTEMI/UA.
Although the recommendations of guidelines are mostly
Table 5 Pharmacological treatment at discharge
Total (n ¼ 5619) PCI (n ¼ 3254) CABG (n ¼ 1188) Medical (n ¼ 1177) P-value
Aspirin, n (%) 4857 (86) 2972 (91) 922 (78) 963 (82) 
Any anti-thrombotic drug, n (%)a 5356 (95) 3179 (98) 1087 (92) 1090 (93) 
Beta-blocker, n (%) 4133 (74) 2442 (75) 833 (70) 858 (73) 
ACE-inhibitor, n (%) 3190 (57) 1845 (57) 590 (50) 755 (64) 
Statin, n (%) 3740 (67) 2301 (71) 643 (54) 796 (68) 
Asterisks denote P  0.001.
aAny anti-thrombotic drug includes anti-platelet drugs and coumadin.
1176 M.J. Lenzen et al.
endorsed, the main area for improvement pertains to the
underuse of adjunctive pharmacology (GP IIb/IIIa inhibi-
tors, statins, and ACE-inhibitors). These data on the indi-
cations for revascularization, the choice between PCI or
CABG and their outcome in the era of bare metal stenting
will serve as a benchmark for the future evaluation of the
impact of drug-eluting stents on the practice of coronary
revascularization.
Appendix: Organization of the survey
Coronary Revascularization Expert Committee: W. Wijns
(Survey Chairman), Belgium; N. Mercado (Research Fellow),
The Netherlands; M. Bertrand, France; W. Maier, Switzerland;
B. Meier, Switzerland; C. Moris, Spain; F. Piscione, Italy;
U. Sechtem, Germany; P. Sergeant, Belgium; E. Stahle,
Sweden; J. Vos, The Netherlands; P. Widimsky, Czech Republic;
F. Unger, Austria.
Euro Heart Survey Team (European Heart House, France):
Malika Manini (Operations Manager); Claire Bramley (Data
Monitor); Vale´rie Laforest (Data Monitor); Charles Taylor (Data-
base Administrator); Susan Del Gaiso (Administrator).
National Coordinators: Austria, Kurt Huber; Belgium, Guy De
Backer; Bulgaria, Vera Sirakova; Czech Republic, Roman
Cerbak; Denmark, Per Thayssen; Finland, Seppo Lehto; France,
Jean-Jacques Blanc, Franc¸ois Delahaye; Georgia, Bondo
Kobulia; Germany, Uwe Zeymer; Greece, Dennis Cokkinos;
Hungary, Kristof Karlocai; Ireland, Ian Graham, Emer Shelley;
Israel, Shlomo Behar; Italy, Aldo Maggioni; Lithuania, Virginija
Grabauskiene; The Netherlands, Jaap Deckers; Norway, Inger
Asmussen; Poland, Janina Stepinska; Portugal, Lino Gonc¸alves;
Russia, Vyacheslav Mareev; Slovakia, Igor Riecansky; Slovenia,
Miran F. Kenda; Spain, Angeles Alonso, Jose´ Luis Lopez-Sendon;
Sweden, Annika Rosengren; Switzerland, Peter Buser; Turkey,
Tugrul Okay; Ukraine, Oleg Sychov; United Kingdom, Kevin Fox.
Euro Heart Survey Board Committee: David Wood (Chairman),
United Kingdom; Angeles Alonso, Spain; Shlomo Behar, Israel;
Eric Boersma, The Netherlands; Harry Crijns, The Netherlands;
Kim Fox, United Kingdom; Malika Manini, France; Keith
McGregor, France; Barbara Mulder, The Netherlands; Sylvia
Priori, Italy; Lars Ryde´n, Sweden; Luigi Tavazzi, Italy; Alec
Vahanian, France; Panos Vardas, Greece; William Wijns,
Belgium; Uwe Zeymer, Germany.
Industry Sponsor: Eucomed.
List of Sponsoring Institutions: French Federation of Cardiology,
Hellenic Cardiological Society, Netherland Heart Foundation,
Swedish Heart and Lung Foundation, and individual hospitals.
Participating Centres, Investigators, and Data Collection Ofﬁ-
cers: Armenia: Karine Sarkisyan, Yerevan. Austria: H.D. Glogar,
Michael Derntl, Vienna; Matthias Frick, O. Pachinger, Ralf
Zwick, Innsbruck. Belgium: Christiaan Vrints, Els Van
Hertbruggen, Marc Vercammen, Tineke Sysmans, Edegem;
E. Schroeder, Juliette Domange, Yvoir; William Wijns, Hilde De
Pril, Aalst; Johan De Vriese, Tonny Van Hecke, Gent;
V. Legrand, Marie-France Gillon, Michel Richardy, P. Doneux,
Liege. Bulgaria: Ivo Petrov, J. Jorgova, Soﬁa; Vera Sirakova,
Varna. Croatia: Boris Starcevic, Zagreb. Switzerland: Eric
Eeckhout, Alexandre Berger, Veronique Prudent, Lausanne;
E. Camenzind, Nicolas Masson, Geneve. Cyprus: Costas
Zambartas, Helen Kleanthous, Nicosia. Czech Republic: Petr
Widimsky, Blanka Stellova, Michael Aschermann, Stanislav
Simek, J. Kautzner, Vladimir Karmazin, P. Svab, Prague; Jan
Indrak, M. Branny, Trinec; Kveta Hladilova, P. Kala, Brno.
Denmark: P. Thayssen, Helle Cappelen, Lisette Okkels Jensen,
Odense. Germany: A. Gitt, Konstanze Gehrke, Ludwigshafen
am Rhein; R. Erbel, Achim Gutersohn, Holger Eggebrecht,
Murad Al Khani, Essen; Udo Sechtem, Antje Rosenberger,
Holger Vogelsberg, Stuttgart; H. Klepzig, Arnold Schmidt, Offen-
bach; Sigmund Silber, Birgit Mau, Munich; Christian Leuner,
Karen Czyborra, Bielefeld; Christina Reuschling, Eva Muno, Bad
Nauheim; F. Kleber, Sascha Rux, Berlin; U. Zeymer, Kassel.
Egypt: Aly Saad, Zagazig; BSS. Ibrahim, Maged Elabady, Cairo.
Spain: A. Castro Beiras, Jorge Salgado Fernandez, La Coruna;
Felipe Navarro del Arno, A. Iniguez Romo, Madrid; J.M. Cruz
Fernandez, Alejandro Recio Mayoreal, Franciso Javier Rivero
Rebanal, Mariano Garcia de la Borbolla, Marinela Chaparro,
Sevilla; C. Brotons, C. Permanyer Miralda, Srta Irma Vila i
Perez, Barcelona; Cesar Moris, Oviedo; F. Fernandez Aviles,
Luis de la Fuente Galan, Paula Tejedor Vinuela, Valladolid;
F. Malpartida de Torres, Javier Mora, Malaga; Ignacio Santos
Rodriguez, Itziar Piedra Bustamante, Pedro L. Sanchez
Fernandez, Salamanca; J.L. Diago Torrent, Jose L. Diez Gil,
Castellon; Javier Perpinan, V. Palacios Motilla, Alzira, Valencia;
M. Soledad Alcasena Juango, Jesus Berjon-Reyero, Pamplona;
R. Melgares Moreno, Juan Carlos Fernandez Guerrero,
Granada. Finland: S. Lehto, Kirsti Savolainen, Kuopio; MS.
Nieminen, Mikko Syvanne, Helsinki. France: A. Cohen-Solal,
Antoine-Sylvain Oboa, Clichy; J.P. Bassand, Denis Pales
Espinosa, Veronique Jouet, Besancon Cedex; G. Montalescot,
Vanessa Gallois, Paris; J.C. Daubert, Jean Michel Clerc,
Rennes; Jacques Machecourt, Grenoble; Y. Cottin, Dijon.
United Kingdom: D. Walker, Fhiona Holland, St Leonards-on-
Sea; D. Wood, Jenni Prosser, Lis Muir, Kate Barber, London;
J.G.F. Cleland, Jocelyn Cook, Kingston upon Hull. Georgia:
Bondo Kobulia, Zaza Chapichadze, Tbilisi. Greece: Ioannis
Skoularigisn Athanasiou Christos, Larisa; Dennis Cokkinos,
Nastasia Tsiavou, Christina Chrysohoou, Athanassios Manginas,
John Terrovitis, John Kanakakis, Manolis Vavuranakis, Stavros
Drakos, Athens; Thomas Farmakis, C. Samara, Thessaloniki;
Christina Papakosta, Christos Bourantas, L.K. Michalis,
Mpourantas Christos, Ioannina; Stefanos Foussas, Evdokia
Adamopoulou, Pireus; P.E. Vardas, Mary Marketou, Heraklion,
Crete. Hungary: N. Alotti, Anna Maria Basa, Andras Vigh,
Zalaegerszeg; Istvan Preda, Eva Csoti, M. Keltai, G. Kerkovits,
Budapest. Israel: Alberto Hendler, Alex Blatt, Beer Yakov;
R. Beyar, Arie Shefer, David Halon, Margalait Bentzvi, Naomi
Avramovitch, Haifa; Avinoam Bakst, Kfar Saba; Carlos Cafri,
Aviva Grosbard, Beer Sheva; Bella Margolis, Khalid Suleiman,
Afula; Shmuel Banai, David Meerkin, Morris Mosseri, Pnina
Guita, Rifat Jabara, Jerusalem; Jamal Jafari, Debi Ben Shitrit,
Ashkelon; Dr Ghasan, Dr Salameh, Tiberias; Marc Brezins, Lily
van den Akker-Berman, Nahariya; Victor Guetta, Tel Hashomer;
Yoseph Rozenman, Holon. Italy: A. Biagini, Sergio Berti, Massa;
Massimo Ferrero, A. Colombo, R. Roccaforte, Caterina Milici,
Milano; L. Scarpino, A. Salvi, Gorizia; Alessandro Desideri,
Daniela Sabbadin, Castelfranco Veneto; Alfredo Galassi,
Giuseppe Giuffrida, Catania; Andrea Rognoni, Corrado
Vassanelli, Paola Paffoni, Novara; Angelo Cioppa, Paolo Rubino,
Mercogliano (Avellino); Marco de Carlo, Anna Sonia Petronio,
Pisa; F. Naccarella, Francesco Saia, Antonio Marzocchi, Stefano
Sdringola Maranga, Bologna; P. Presbitero, Fazya Valsecchi,
Rozzano-Milan; Federico Piscione, Giovanni Esposito, Napoli
M. Santini, Marco Tubaro, Rome. Lithuania: A. Erglis, Inga
Narbute, Riga; Ausra Kavoliuniene, R. Zaliunas, Ramunas
Navickas, Kaunas; V. Grabauskiene, Davia Luckute, Eduardas
Subkovas, Vilnius. Luxembourg: Daniel Wagner. The
Netherlands: F. Vermeer, Aimee Lousberg, Heidi Fransen,
Maastricht; Arno Breeman, Henriette Tebbe, M.J. De Boer,
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Metske van der Wal, Zwolle; J. Deckers, Jeroen Vos, C.M.
Leenders, M.J. Veerhoek, Chris Jansen, Rotterdam; M. Bijl,
Colinda Koppelaar, Dordrecht; Dr Van den Linden, Colinda
Koppelaar, Vlaardingen; R. Brons, Henriette Tebbe, Meppel;
J.W.M.G. Widdershofen, Herman Broers, Tilburg. Norway:
F. Kontny, Marianne Jonzon, Oslo. Poland: Jan Wodniecki,
Andrzej Tomasik, Zabrze; M. Trusz-Gluza, Seweryn Nowak,
Katowice; Witold Ruzyllo, Tomasz Deptuch, Warsaw. Portugal:
Jorge Marques, F. Matias, Almada; H. Madeira, Joaquim
Oliveira, Luis Sargento, Lisbon. Romania: Adina Ionac, Iosif
Stefan Dragulescu, Bogdan Mut-Vitcu, Daniela Maximov,
Timisoara; M. Dorobantu, E. Apetrei, Rodica Niculescu, Virgil
Petrescu, Adrian Bucsa, Dan Deleanu, Bucharest; I.S. Benedek,
Theodora Hintea, Targu-Mures. Russian Federation: D. Aronov,
Elena Tikhomirova, Moscow. Slovenia: I. Kranjec, Katja
Prokselj, Ljubljana; Vojko Kanic, Maribor. Turkey: Tugrul Okay,
Ahmet Sepetoglu, Istanbul; S. Aytekin, V. Aytekin, Alp Burak
Catakoglu, Hayri Parlar, Suavi Tufekcioglu, Zeki Ozyedek, Sisli;
Mehmet Baltali, Dr Kiziltan, Adana. Serbia & Montenegro:
Milan Vukovic, A.N. Neskovic, Belgrade.
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